Experimental Lung Research · 2019 · 37 citations · 27 references
MedicineMolecular MedicinePharmacologyCell SignalingDrug DiscoveryMolecular PharmacologyAntifibrotic TherapyFibrosisInterstitial Lung DiseasePulmonary InflammationWnt SignalingCanonical Beta-catenin SignalingCanonical Wnt Beta-catenin PathwayCanonical Wnt PathwayPulmonary Fibrosis ProgressionWestern BlottingWnt Signal TransductionWnt Signaling ActivationWnt Signaling Modulation
Purpose/Aim of the Study: Wnt/β-catenin signaling was reported to be activated in pulmonary fibrosis, and was focused on as a target for antifibrotic therapy. However, the mechanism how the inhibition of Wnt/β-catenin signaling ameliorate pulmonary fibrosis has not been fully elucidated. The purpose of this study is to explore the target cells of Wnt/β-catenin inhibition in pulmonary fibrosis and to examine the antifibrotic effect of the novel inhibitor PRI-724 specifically disrupting the interaction of β-catenin and CBP. Materials and Methods: The effect of C-82, an active metabolite of PRI-724, on the expression of TGF-β1 and α-smooth muscle actin (SMA) was examined on fibroblasts and macrophages. We also examined the effects of PRI-724 in mouse model of bleomycin-induced pulmonary fibrosis. Results: The activation and increased accumulation of β-catenin in the canonical pathway were detected in lung fibroblasts as well as macrophages stimulated by Wnt3a using Western blotting. Treatment with C-82 reduced CBP protein and increased p300 protein binding to β-catenin in the nucleus of lung fibroblasts. In addition, C-82 inhibited the expression of SMA in lung fibroblasts treated with TGF-β, indicating the inhibition of myofibroblast differentiation. In the fibrotic lungs induced by bleomycin, β-catenin was stained strongly in macrophages, but the staining of β-catenin in alveolar epithelial cells and fibroblasts was weak. The administration of PRI-724 ameliorated pulmonary fibrosis induced by bleomycin in mice when administered with a late, but not an early, treatment schedule. Analysis of bronchoalveolar fluid (BALF) showed a decreased number of alveolar macrophages. In addition, the level of TGF-β1 in BALF was decreased in mice treated with PRI-724. C-82 also inhibited the production of TGF-β1 by alveolar macrophages. Conclusions: These results suggest that the β-catenin/CBP inhibitor PRI-724 is a potent antifibrotic agent that acts by modulating the activity of macrophages in the lungs.
27
Ganesh Raghu, Bram Rochwerg, Yuan Zhang et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 1.9K citations
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
Alfiya Akhmetshina, Katrin Palumbo, Clara Dees et al. · Nature Communications · 2012 · 831 citations · Full text
Aberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
Marco Chilosi, Venerino Poletti, Alberto Zamò et al. · American Journal Of Pathology · 2003 · 710 citations · Full text
Mélanie Königshoff, Monika Kramer, N Balsara et al. · Journal of Clinical Investigation · 2009 · 554 citations · Full text